Hereditary Angioedema
Conditions
Brief summary
The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. Lanadelumab, also known as TAK-743, is a medicine to help prevent hereditary angioedema attacks. Lanadelumab is not yet licensed for use in Japan. The main aim of this study is to allow Japanese teenagers and adults with type I or type II hereditary angioedema to be treated with lanadelumab, through the expanded access program in Japan. Participants can either have taken part in the previous study SHP643-302 or can be new participants. Participants just completing study SHP643-302 who reach the criteria can automatically take part in this study. However, for new participants, the study doctor will check who can take part at the first study visit. For those who can take part, new participants will receive injections of lanadelumab just under the skin. Eventually, after training, some of these will be able to inject themselves with lanadelumab in the same way. Participants who injected themselves with lanadelumab in study SHP643-302 can continue to do so during this study. The study doctors will decide if each participant will be treated with lanadelumab every 2 weeks or every 4 weeks. Treatment with lanadelumab will continue until lanadelumab is commercially available in Japan or the sponsor (Takeda) stops the study. Participants can visit the clinic during treatment if needed. If treatment continues after 6 months, participants will visit the clinic every 12 weeks for a check-up. This will include noting any hereditary angioedema attacks and side effects from the treatment. After 7 months of treatment, the study staff will check-up with each participant every 2 weeks by telephone. After treatment has finished, participants will visit the clinic for a final-check-up 4 weeks later.
Detailed description
This study is Japan Expanded Access Program with TAK-743. The study drug in this study is called TAK-743. TAK-743 will be administered to people who have Type I or II hereditary angioedema (HAE). Two types of participants will be enrolled into this study: * Participants who rollover from Study SHP643-302 (NCT04180163). * Participants who are non-rollovers (ie, were not participants in Study SHP643-302). Participants who discontinue from Study SHP643-302 after providing informed consent are not eligible to enroll in this study. All participants will be asked to administer TAK-743 300 mg with subcutaneous injection every 2 weeks throughout this study. Participants who is stable with over 6-month administration of 300mg every 2 weeks can be switched to 300mg every 4 weeks. This multi-center trial will be conducted in Japan (approximately 15 sites). The overall time to participate in this study is over 182 days. Participants will make multiple visits to the clinic basically every 2 weeks until Day 182, and will be contacted by telephone every 2 weeks after Day 182 plus multiple visit every 12 weeks after Day 182 for a follow-up assessment until study completion.
Interventions
DRUGTAK-743 300 mg
TAK-743 300 mg, subcutaneous injection every 2 or 4 weeks
Sponsors
Takeda
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. In the opinion of the Investigator, the participant is capable of understanding and complying with protocol requirements. 2. Be of Japanese descent, defined as born in Japan and having Japanese parents and Japanese maternal and paternal grandparents. 3. Male and female HAE participants who are 12 years of age or older at the time of screening. 4. Documented diagnosis of disease HAE (Type I or II) based on all of the following: * Documented clinical history consistent with HAE (subcutaneous \[SC\] or mucosal, nonpruritic swelling episodes without accompanying urticaria). * Diagnostic testing results obtained during screening (or a prior lanadelumab study) that confirm HAE Type I or II: C1-inhibitor (C1-INH) functional level \<40% of the normal level. Participants with functional C1-INH level 40% to 50% of the normal level may be enrolled if they also have a C4 level below the normal range. Participants may be retested if results are incongruent with clinical history or believed by the Investigator to be confounded by long-term prophylaxis (LTP) use. It is understood that C1-INH therapy may alter the lab results of C1-INH assessments; therefore, the Investigator's discretion in collaboration with sponsor is advised for proper documentation of eligibility. * At least one of the following: Age at reported onset of first angioedema symptoms =\<30 years, a family history consistent with HAE Type I or II, or C1q within normal range. 5. Non-rollover participants only: A historical baseline HAE attack rate of at least 1 attack per 4 weeks in the recent 1 year. 6. Rollover participants only: Participants from Study SHP643-302 are permitted to rollover and enroll into this study if: * They completed the treatment period of Study SHP643-302; and * They consented to enter Study TAK-743-5007 on or before Day 350 of the SHP643-302 study (since Day 378 of Study SHP643-302 is also Day 0 of Study TAK-743-5007, informed consent may be completed on Day 364 or this visit, if not already provided). 7. Adult participants and caregivers of subjects under the age of 20 are willing and able to read, understand, and sign an informed consent form. Participants aged 12 to 19, whose caregiver has provided informed consent, are willing and able to read, understand and sign an informed consent form (an assent form, if applicable) as much as possible. 8. Agree to adhere to the protocol-defined schedule of treatments, assessments, and procedures. 9. Males and females who are fertile and sexually active must adhere to contraception requirements for the duration of the study as follows: * Females of childbearing potential must agree to be abstinent or it is recommended to use highly effective forms of contraception from the screening period through 70 days after the final study visit. * Females of nonchildbearing potential, defined as surgically sterile (status post-hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or postmenopausal for at least 12 months do not require contraception during the study. * Males, including males who are surgically sterile (post-vasectomy), with female partners of childbearing potential must agree to be abstinent or else use a medically acceptable form of contraception from the screening period through 70 days after the final study visit.
Exclusion criteria
1. If rolling over from Study SHP643-302, presence of important safety concerns that would preclude participation in this study. 2. Concomitant diagnosis of another form of chronic, recurrent angioedema such as acquired angioedema, HAE with normal C1-INH (also known as HAE Type III/normal C1-INH), idiopathic angioedema, or recurrent angioedema associated with urticaria. 3. Dosing with an investigational drug (not including lanadelumab or other HAE therapies) or exposure to an investigational device within 4 weeks prior to screening. 4. Exposure to angiotensin-converting enzyme (ACE) inhibitors within 4 weeks prior to screening or any newly initiated or dose modification of estrogen-containing medications with systemic absorption (such as oral contraceptives or hormonal replacement therapy) 3 months prior to the screening visit. 5. Unwilling to discontinue short or long-term prophylactic therapy for HAE, eg, C1-INH, attenuated androgens or anti-fibrinolytics within 3 weeks after starting the treatment period. Short-term prophylaxis is defined as C1-INH, attenuated androgens, or antifibrinolytic used to avoid angioedema complications from medically indicated procedures. 6. Any of the following liver function test abnormalities: alanine aminotransferase (ALT) \>3 × upper limit of normal (ULN), or aspartate aminotransferase (AST) \>3 × ULN, or total bilirubin \>2 × ULN (unless the bilirubin elevation is a result of Gilbert's syndrome). 7. Pregnancy or breast feeding. 8. Have any uncontrolled underlying medical condition which would require treatment adjustment during the study treatment period, that, in the opinion of the Investigator or sponsor, may confound the results of the safety assessments or may place the participant at risk. Participants with stable treatment for at least 3 months prior to screening and NOT expecting any change to their treatment regimen for 6 months during the study treatment period, will not be excluded. 9. Participant has a known hypersensitivity to the study drug or its components.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | From start of study drug administration (in current study) up to end of study (EOS) (Day 294) | TEAEs were defined as adverse events (AEs) with onset at the time of or following the first exposure to lanadelumab in this study, or medical conditions present prior to the start of treatment but increasing in severity or relationship at the time of or following the start of treatment. Serious TEAEs were defined as any untoward clinical manifestation of signs, symptoms, outcomes (related to IP or not) that at any dose: resulted in death, was life-threatening, required inpatient/prolongation of hospitalization, resulted in persistent/significant disability/incapacity, congenital abnormality/birth defect, important medical event. AESI were defined as investigator-reported hypersensitivity reactions, events of disordered coagulation as bleeding/hypercoagulable. Relatedness to study drug was based on Investigator's discretion. TEAEs were classified and reported as Hereditary Angioedema (HAE) attack and non-HAE attack AEs in this outcome measure. |
| Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Tests | From start of study drug administration (in current study) up to EOS (Day 294) | Clinical laboratory testing included clinical serum chemistry, hematology, coagulation and urinalysis. Any change in clinical laboratory abnormalities which were deemed clinically significant by the investigator were recorded as TEAEs. |
| Number of Participants With Clinically Significant Abnormalities in Vital Signs | From start of study drug administration (in current study) up to EOS (Day 294) | Vital signs parameters included blood pressure, heart rate, body temperature and respiratory rate. Any change in vital sign abnormalities which were deemed clinically significant by the investigator were recorded as TEAEs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to First HAE Attack After Day 0 for the Efficacy Evaluation Period for Non-Rollover Participants | Day 0 (in current study) through Day 182 | A HAE attack was defined as the symptoms or signs consistent with an attack in at least 1 of the following locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). The time to the first HAE attack (days) was calculated from the date and time of the first dose of lanadelumab for the efficacy evaluation period (Day 0 through Day 182) to the date and time of the first in HAE attack after the first open-label dose for the efficacy evaluation period of Day 0 through Day 182. The time to the first Investigator-confirmed HAE attack (days) was summarized using Kaplan-Meier (KM) methods. |
Countries
Japan
Participant flow
Recruitment details
This study was conducted at 9 investigative centers in Japan from 10 February 2021 to 18 June 2022.
Pre-assignment details
A total of 12 participants with type I and II hereditary angioderma (HAE) participated in this study. Two types of participants were enrolled into this study: Participants who rolled over from Study SHP643-302 (NCT04180163) and participants who were non-rollovers (i.e., were not participants in Study SHP643-302 \[NCT04180163\]).
Participants by arm
| Arm | Count |
|---|---|
| Rollover Participants Rollover participants from Study SHP643-302 (NCT04180163) in this group received lanadelumab 300 mg SC injection on Day 0 followed by q2w or q4w if well-controlled (attack-free) for 26 consecutive weeks with lanadelumab treatment based on Investigator's discretion. | 11 |
| Non-rollover Participants Non-rollover participants in this group received lanadelumab 300 mg SC on Day 0 followed by q2w or q4w if well-controlled (attack-free) for 26 consecutive weeks with lanadelumab treatment based on Investigator's discretion. | 1 |
| Total | 12 |
Baseline characteristics
| Characteristic | Rollover Participants | Total | Non-rollover Participants |
|---|---|---|---|
| Age, Continuous | 42.4 years STANDARD_DEVIATION 12.56 | 42.3 years STANDARD_DEVIATION 11.98 | 41.0 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 11 Participants | 12 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 11 Participants | 12 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Japan | 11 Participants | 12 Participants | 1 Participants |
| Sex: Female, Male Female | 8 Participants | 9 Participants | 1 Participants |
| Sex: Female, Male Male | 3 Participants | 3 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 11 | 0 / 1 |
| other Total, other adverse events | 11 / 11 | 1 / 1 |
| serious Total, serious adverse events | 1 / 11 | 0 / 1 |
Outcome results
Primary
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Tests
Clinical laboratory testing included clinical serum chemistry, hematology, coagulation and urinalysis. Any change in clinical laboratory abnormalities which were deemed clinically significant by the investigator were recorded as TEAEs.
Time frame: From start of study drug administration (in current study) up to EOS (Day 294)
Population: FAS included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Rollover Participants | Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Tests | 0 Participants |
| Non-rollover Participants | Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Tests | 0 Participants |
Primary
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Vital signs parameters included blood pressure, heart rate, body temperature and respiratory rate. Any change in vital sign abnormalities which were deemed clinically significant by the investigator were recorded as TEAEs.
Time frame: From start of study drug administration (in current study) up to EOS (Day 294)
Population: FAS included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Rollover Participants | Number of Participants With Clinically Significant Abnormalities in Vital Signs | 0 Participants |
| Non-rollover Participants | Number of Participants With Clinically Significant Abnormalities in Vital Signs | 0 Participants |
Primary
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI)
TEAEs were defined as adverse events (AEs) with onset at the time of or following the first exposure to lanadelumab in this study, or medical conditions present prior to the start of treatment but increasing in severity or relationship at the time of or following the start of treatment. Serious TEAEs were defined as any untoward clinical manifestation of signs, symptoms, outcomes (related to IP or not) that at any dose: resulted in death, was life-threatening, required inpatient/prolongation of hospitalization, resulted in persistent/significant disability/incapacity, congenital abnormality/birth defect, important medical event. AESI were defined as investigator-reported hypersensitivity reactions, events of disordered coagulation as bleeding/hypercoagulable. Relatedness to study drug was based on Investigator's discretion. TEAEs were classified and reported as Hereditary Angioedema (HAE) attack and non-HAE attack AEs in this outcome measure.
Time frame: From start of study drug administration (in current study) up to end of study (EOS) (Day 294)
Population: FAS included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | Any TEAEs: Non-HAE | 11 Participants |
| Rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | Any TEAEs: HAE | 8 Participants |
| Rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | AESI: Non-HAE | 1 Participants |
| Rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | AESI: HAE | 0 Participants |
| Rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | Any Serious TEAEs: Non-HAE | 1 Participants |
| Rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | Any Serious TEAEs: HAE | 1 Participants |
| Non-rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | Any Serious TEAEs: Non-HAE | 0 Participants |
| Non-rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | Any TEAEs: Non-HAE | 1 Participants |
| Non-rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | AESI: HAE | 0 Participants |
| Non-rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | Any TEAEs: HAE | 1 Participants |
| Non-rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | Any Serious TEAEs: HAE | 0 Participants |
| Non-rollover Participants | Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) | AESI: Non-HAE | 0 Participants |
Secondary
Time to First HAE Attack After Day 0 for the Efficacy Evaluation Period for Non-Rollover Participants
A HAE attack was defined as the symptoms or signs consistent with an attack in at least 1 of the following locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). The time to the first HAE attack (days) was calculated from the date and time of the first dose of lanadelumab for the efficacy evaluation period (Day 0 through Day 182) to the date and time of the first in HAE attack after the first open-label dose for the efficacy evaluation period of Day 0 through Day 182. The time to the first Investigator-confirmed HAE attack (days) was summarized using Kaplan-Meier (KM) methods.
Time frame: Day 0 (in current study) through Day 182
Population: FAS included all participants who received at least 1 dose of study drug. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure. Data was not collected and analyzed for rollover participants as pre-specified in protocol.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Rollover Participants | Time to First HAE Attack After Day 0 for the Efficacy Evaluation Period for Non-Rollover Participants | 0.0 days |